| Year |
Citation |
Score |
| 2011 |
McCoy MK, Ruhn KA, Blesch A, Tansey MG. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. Advances in Experimental Medicine and Biology. 691: 539-40. PMID 21153359 DOI: 10.1007/978-1-4419-6612-4_56 |
0.772 |
|
| 2008 |
McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. Journal of Neuroinflammation. 5: 45. PMID 18925972 DOI: 10.1186/1742-2094-5-45 |
0.69 |
|
| 2008 |
Lee JK, McCoy MK, Harms AS, Ruhn KA, Gold SJ, Tansey MG. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 8517-28. PMID 18716210 DOI: 10.1523/Jneurosci.1806-08.2008 |
0.836 |
|
| 2008 |
McCoy MK, Ruhn KA, Martinez TN, McAlpine FE, Blesch A, Tansey MG. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1572-9. PMID 18628756 DOI: 10.1038/Mt.2008.146 |
0.744 |
|
| 2008 |
Tran TA, McCoy MK, Sporn MB, Tansey MG. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. Journal of Neuroinflammation. 5: 14. PMID 18474101 DOI: 10.1186/1742-2094-5-14 |
0.671 |
|
| 2008 |
McCoy MK, Martinez TN, Ruhn KA, Wrage PC, Keefer EW, Botterman BR, Tansey KE, Tansey MG. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Experimental Neurology. 210: 14-29. PMID 18061169 DOI: 10.1016/J.Expneurol.2007.10.011 |
0.674 |
|
| 2008 |
Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, Ruhn KA, Tran TA. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Frontiers in Bioscience : a Journal and Virtual Library. 13: 709-17. PMID 17981581 DOI: 10.2741/2713 |
0.628 |
|
| 2007 |
Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology. 208: 1-25. PMID 17720159 DOI: 10.1016/J.Expneurol.2007.07.004 |
0.802 |
|
| 2006 |
McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 9365-75. PMID 16971520 DOI: 10.1523/Jneurosci.1504-06.2006 |
0.844 |
|
| Show low-probability matches. |